Cargando…

CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity

Metastatic progression and tumor evolution complicates the clinical management of cancer patients. Circulating tumor cell (CTC) characterization is a growing discipline that aims to elucidate tumor metastasis and evolution processes. CTCs offer the clinical potential to monitor cancer patients for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ffrench, B., Kashdan, E., Huang, Y., Spillane, C.D., Cocchiglia, S., Charmsaz, S., Varešlija, D., O'Brien, C., Scholz, D., Martin, C., Gallagher, M., Brooks, D.A., Brooks, R.D., Selemidis, S., Gleeson, N., AbuSaadeh, F., O'Riain, C., Kamran, W., Flavin, R., Young, L., O'Toole, S.A., O'Leary, J.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898658/
https://www.ncbi.nlm.nih.gov/pubmed/36747925
http://dx.doi.org/10.1016/j.heliyon.2023.e13044
_version_ 1784882472826175488
author Ffrench, B.
Kashdan, E.
Huang, Y.
Spillane, C.D.
Cocchiglia, S.
Charmsaz, S.
Varešlija, D.
O'Brien, C.
Scholz, D.
Martin, C.
Gallagher, M.
Brooks, D.A.
Brooks, R.D.
Selemidis, S.
Gleeson, N.
AbuSaadeh, F.
O'Riain, C.
Kamran, W.
Flavin, R.
Young, L.
O'Toole, S.A.
O'Leary, J.J.
author_facet Ffrench, B.
Kashdan, E.
Huang, Y.
Spillane, C.D.
Cocchiglia, S.
Charmsaz, S.
Varešlija, D.
O'Brien, C.
Scholz, D.
Martin, C.
Gallagher, M.
Brooks, D.A.
Brooks, R.D.
Selemidis, S.
Gleeson, N.
AbuSaadeh, F.
O'Riain, C.
Kamran, W.
Flavin, R.
Young, L.
O'Toole, S.A.
O'Leary, J.J.
author_sort Ffrench, B.
collection PubMed
description Metastatic progression and tumor evolution complicates the clinical management of cancer patients. Circulating tumor cell (CTC) characterization is a growing discipline that aims to elucidate tumor metastasis and evolution processes. CTCs offer the clinical potential to monitor cancer patients for therapy response, disease relapse, and screen ‘at risk' groups for the onset of malignancy. However, such clinical utility is currently limited to breast, prostate, and colorectal cancer patients. Further understanding of the basic CTC biology of other malignancies is required to progress them towards clinical utility. Unfortunately, such basic clinical research is often limited by restrictive characterization methods and high-cost barrier to entry for CTC isolation and imaging infrastructure. As experimental clinical results on applications of CTC are accumulating, it is becoming clear that a two-tier system of CTC isolation and characterization is required. The first tier is to facilitate basic research into CTC characterization. This basic research then informs a second tier specialised in clinical prognostic and diagnostic testing. This study presented in this manuscript describes the development and application of a low-cost, CTC isolation and characterization pipeline; CTC-5. This approach uses an established ‘isolation by size’ approach (ScreenCell Cyto) and combines histochemical morphology stains and multiparametric immunofluorescence on the same isolated CTCs. This enables capture and characterization of CTCs independent of biomarker-based pre-selection and accommodates both single CTCs and clusters of CTCs. Additionally, the developed open-source software is provided to facilitate the synchronization of microscopy data from multiple sources (https://github.com/CTC5/). This enables high parameter histochemical and immunofluorescent analysis of CTCs with existing microscopy infrastructure without investment in CTC specific imaging hardware. Our approach confirmed by the number of successful tests represents a potential major advance towards highly accessible low-cost technology aiming at the basic research tier of CTC isolation and characterization. The biomarker independent approach facilitates closing the gap between malignancies with poorly, and well-defined CTC phenotypes. As is currently the case for some of the most commonly occurring breast, prostate and colorectal cancers, such advances will ultimately benefit the patient, as early detection of relapse or onset of malignancy strongly correlates with their prognosis.
format Online
Article
Text
id pubmed-9898658
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98986582023-02-05 CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity Ffrench, B. Kashdan, E. Huang, Y. Spillane, C.D. Cocchiglia, S. Charmsaz, S. Varešlija, D. O'Brien, C. Scholz, D. Martin, C. Gallagher, M. Brooks, D.A. Brooks, R.D. Selemidis, S. Gleeson, N. AbuSaadeh, F. O'Riain, C. Kamran, W. Flavin, R. Young, L. O'Toole, S.A. O'Leary, J.J. Heliyon Research Article Metastatic progression and tumor evolution complicates the clinical management of cancer patients. Circulating tumor cell (CTC) characterization is a growing discipline that aims to elucidate tumor metastasis and evolution processes. CTCs offer the clinical potential to monitor cancer patients for therapy response, disease relapse, and screen ‘at risk' groups for the onset of malignancy. However, such clinical utility is currently limited to breast, prostate, and colorectal cancer patients. Further understanding of the basic CTC biology of other malignancies is required to progress them towards clinical utility. Unfortunately, such basic clinical research is often limited by restrictive characterization methods and high-cost barrier to entry for CTC isolation and imaging infrastructure. As experimental clinical results on applications of CTC are accumulating, it is becoming clear that a two-tier system of CTC isolation and characterization is required. The first tier is to facilitate basic research into CTC characterization. This basic research then informs a second tier specialised in clinical prognostic and diagnostic testing. This study presented in this manuscript describes the development and application of a low-cost, CTC isolation and characterization pipeline; CTC-5. This approach uses an established ‘isolation by size’ approach (ScreenCell Cyto) and combines histochemical morphology stains and multiparametric immunofluorescence on the same isolated CTCs. This enables capture and characterization of CTCs independent of biomarker-based pre-selection and accommodates both single CTCs and clusters of CTCs. Additionally, the developed open-source software is provided to facilitate the synchronization of microscopy data from multiple sources (https://github.com/CTC5/). This enables high parameter histochemical and immunofluorescent analysis of CTCs with existing microscopy infrastructure without investment in CTC specific imaging hardware. Our approach confirmed by the number of successful tests represents a potential major advance towards highly accessible low-cost technology aiming at the basic research tier of CTC isolation and characterization. The biomarker independent approach facilitates closing the gap between malignancies with poorly, and well-defined CTC phenotypes. As is currently the case for some of the most commonly occurring breast, prostate and colorectal cancers, such advances will ultimately benefit the patient, as early detection of relapse or onset of malignancy strongly correlates with their prognosis. Elsevier 2023-01-18 /pmc/articles/PMC9898658/ /pubmed/36747925 http://dx.doi.org/10.1016/j.heliyon.2023.e13044 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Ffrench, B.
Kashdan, E.
Huang, Y.
Spillane, C.D.
Cocchiglia, S.
Charmsaz, S.
Varešlija, D.
O'Brien, C.
Scholz, D.
Martin, C.
Gallagher, M.
Brooks, D.A.
Brooks, R.D.
Selemidis, S.
Gleeson, N.
AbuSaadeh, F.
O'Riain, C.
Kamran, W.
Flavin, R.
Young, L.
O'Toole, S.A.
O'Leary, J.J.
CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
title CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
title_full CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
title_fullStr CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
title_full_unstemmed CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
title_short CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity
title_sort ctc-5: a novel digital pathology approach to characterise circulating tumour cell biodiversity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898658/
https://www.ncbi.nlm.nih.gov/pubmed/36747925
http://dx.doi.org/10.1016/j.heliyon.2023.e13044
work_keys_str_mv AT ffrenchb ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT kashdane ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT huangy ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT spillanecd ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT cocchiglias ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT charmsazs ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT vareslijad ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT obrienc ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT scholzd ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT martinc ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT gallagherm ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT brooksda ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT brooksrd ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT selemidiss ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT gleesonn ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT abusaadehf ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT oriainc ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT kamranw ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT flavinr ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT youngl ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT otoolesa ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity
AT olearyjj ctc5anoveldigitalpathologyapproachtocharacterisecirculatingtumourcellbiodiversity